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ABSTRACT
PRECIPITATION OF ULTRAFINE PARTICLES USING LIQUID
ANTISOLVENT WITH CONCENTRIC ULTRASONIC NOZZLE AND
SUBCRITICAL CO 2
by
Satya Chaitanya Kunchala

Nanotechnology has become more relevant in the pharmaceutical industry. Almost 40%
of the drugs developed by pharmaceutical industries are poorly soluble in water which
limits the bioavailability of these drugs in body fluids. Hence, it is necessary to reduce
the particle size, which increases the interfacial surface area. This work focuses on
micronization of class ii drug Griseofulvin which is poorly water soluble. Two processes
namely, liquid antisolvent precipitation using ultrasonic nozzle and other process using
subcritical CO2 have been used to produce ultrafine particles of this drug.
In liquid antisolvent precipitation, a combination of ultrasound, polymer and
surfactant is used to precipitate ultrafine particles. Ultrasound is used to increase the
nucleation rate by enhancing the micro mixing of solvent and antisolvent stream and
decrease the agglomeration. Surfactants and polymers are used to reduce the surface
tension and thereby increase the nucleation rate. Use of additives can inhibit the particle
growth and reduce the agglomeration. Particles in the range of 10 - 2 μm have been
precipitated in this process.
The process using subcritical CO 2 has also been used to increase the micro mixing
and to increase the nucleation rate. The depressurization of CO 2 expanded solutions of
Griseofulvin, causes large temperature drop and hence induce low supersaturation and

high nucleation rate. This results in precipitation of ultrafine particles. Particles in the
range of 15 - 1 [an have been precipitated in this process.
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CHAPTER 1
INTRODUCTION

1.1

Nanotechnology

In recent years, particulate materials of sizes ranging from centimeters to nano meters
have received considerable attention from science and industries such as materials and
manufacturing, chemical and pharmaceutical, medicine and healthcare, environment and
energy, biotechnology and agriculture, electronics, computation and information
technology. As the particle size changes from centimeters to nano meters, material
properties also change. Nanoparticles exhibit many special chemical, mechanical,
optical, magnetic and electrical properties. Nanoparticles fall into three major groups E l l.
•

Natural nanoparticles -- Naturally formed nano particles. Examples: volcanic
ash, ocean spray, magnetotactic bacteria, mineral
composites, and other
existing particles in the environment.

•

Incidental nanoparticles -- By-products produced from industrial processes.

•

Engineered nanoparticles — Specially designed particles to serve certain purpose.
Example: fullerene C60 - used for fuel cell applications.
The process and technology, which purposely produces the materials, by

manipulating their atoms, is called Nanotechnology. The main principle of
nanotechnology is to build chemically stable structures that do not violate existing
physical law Ill. It involves working with materials and devices that are at the nanoscale
level. A nanometer is one billionth of a meter. That is, about 1/80,000 of the diameter of
a human hair, or ten times the diameter of a hydrogen atom

[21 .

Scientists are very much

interested in producing nano materials because these materials will have either enhanced
or entirely new different properties from their parent particles. Nanoparticles drastically

1
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change the bulk properties of the materials. According to material science models,
composites made of particles of size smaller than 100nm, are much stronger than the
ordinary composites made of particles with sizes greater than 100nm. These drastic
changes stern from the weird world of quantum physics. Usually bulk properties of any
material can be calculated by averaging the quantum forces affecting the atoms. As the
size becomes smaller and smaller, there will be a point where the averaging does not
works [31 . The properties of materials can be different at the nanoscale for two main
reasons [31
•

Nanomaterials have a relatively larger surface area when compared to the same
mass of material produced in a larger form. This can make materials more
chemically reactive (in some cases materials that are inert in their larger form
are reactive when produced in their nanoscale form), and affect their strength or
electrical properties.

•

Quantum effects can begin to dominate the behavior of matter at the nanoscale
particularly at the lower end, affecting the optical, electrical and magnetic
behavior of materials. At nanoscale, materials can be produced in one dimension
such as, thin surface coatings, in two dimensions such as, nanowires and
nanotubes and in three dimensions such as, nanoparticles.

3
1.2 Applications of Nanotechnology
Nanotechnology is the revolutionary science and art of manipulating the matter at atomic
or molecular scale that has cut across such disciplines as chemistry, physics, biology, and
engineering 141 . The products of advanced nanotechnology that will become available in
coming decades promise even more revolutionary applications than the products of
current and near-term nanotechnology. Applications in medicine and environment are
very important to discuss.

1.2.1 Applications in Medicine
Nanomaterials have received grater interest in the pharmaceutical field. Due to advances
in nano technology, effective delivery of pharmaceuticals is possible with nanoparticles.
In drug delivery pharmacokinetics and pharmacodynamics plays a vital role.
Pharmacokinetics deals with drug delivery inside the human body. When drug
administered intravenously, it goes through a number of stages such as absorption,
distribution, metabolism & elimination. Drug efficacy mainly depends on the
physiochemical properties of the drug (molecular weight, charge, and aqueous solubility)
and therefore on its chemical structure. Main purpose of many drug delivery systems is
targeted drug delivery. A successful drug delivery system should demonstrate the
properties like optimal drug loading and release, longer shelf life and lower toxicity.
Nanoparticles are desirable for drug delivery because of many important properties like
high drug solubility, lower toxicity, bioavailability and targeted drug delivery

[5]

Nanomachines can deliver drugs to targeted sites within a patient's body. Specific
nanomachines can remove obstacles in the circulatory system and used in identifying and
killing the tumor cells [2].

.

4
Table 1.1 Applications of Nanotechnology in Medicine

[6]

Nanodevices, such as the respirocyte (artificial red blood cell) can replace
defective or improperly functioning cells. Applications of these respirocytes include
transfusable blood substitution, partial treatment of anemia, prenatal/neonatal problems,
and lung disorders [71 Other applications of nanotechnology are nanorobots. In human
.

body, nanorobots can monitor the levels of different compounds and record the
information in the internal memory. In a given tissue, nanorobots in detail can examine
biochemical, biomechanical and histometrical features [21.

1.2.2 Environmental Applications
Nanotechnology offers new and improved environmental applications. However, this
technology has some problems, such as new toxins and related environmental hazards,
associated with it. Nanotechnology is playing an important role in pollution reduction.
Home lighting based on this technology could reduce energy consumption by 10% in the
United States, saving $100 billion annually and reducing carbon emissions by 200
million tons per year

[8]

Nanostructured catalysts can make chemical manufacturing more

efficient by providing higher selectivity for desired reaction products Pi. Nanotechnology
applications can be helpful in creating the substances that replace currently used toxic
materials. For example, nontoxic, energy-efficient computer monitors are replacing those
made of cathode ray tubes (CRT), which contain many toxic materials

[10] .

Nanotechnology plays an important role in remediation and end-of-pipe treatment
technologies. Varieties of nanoparticles are used for the treatment and remediation of
pollutants in the environment. Nanoparticles can also exhibit unique chemical reactivity
which is not observed in larger particles. Scientists are more interested in manipulating
the surface of nanoparticles with organic or inorganic dyes in order to extend their photo
response from UV to visible light, to make them more efficient as photo catalysts for the
transformation of environmental contaminants

[111 .

An example of environmental

treatment and remediation-related application of nanomaterials includes using
nanostructures for polymer-supported ultra filtration (PSUF)

[12].

Rapid and precise sensors made of nanoparticles are capable of detecting
pollutants at the molecular level. These are greatly helpful to protect human health and
the environment. Nanotube sensors exhibit fast responses at room temperature to the
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gases and these are more sensitive than existing solid-state sensors

[131 .

Human health and

ecological diagnosis could also benefit from sensors. Nanobarcodes can greatly enhance
our ability to identify the source and strength of contaminants, determine the route and
mechanism of environmental fate and bioavailability, and assess the effectiveness of
treatment and remediation techniques [141 Manufacturing process control, compliance,
.

ecosystem monitoring, and environmental decision-making would be significantly
improved - if more sensitive and less costly techniques for contaminant detection were
available [131

.

Nanotechnology is a revolutionary scientific and engineering venture that will
invariably impact the existing infrastructure of consumer goods, manufacturing methods,
and materials usage. Not surprisingly, the potential benefits have dominated scientific
and mass media coverage of nanotechnology. But any technology can be a double-edged
sword. We are already witnessing some precursors of nanotechnology-associated
pollution. Toxic gallium arsenide used in microchips enters landfills in increasing
quantities as millions of computers and cellular phones are disposed of every year.
Potentially harmful effects of nanotechnology might arise as a result of the nature of
nanomaterials themselves, the characteristics of the products made from them, or the
aspects of the manufacturing process involved . The large surface area, crystalline
.

structure, and reactivity of some nanoparticles, for instance, may facilitate transport of
toxic materials in the environment, or the size and chemical composition of
nanostructures may lead to biological harm because of the way they interact with cellular
materials [151 Because nanotechnology is unlikely to be an entirely benign technology
.

advance, there is an urgent need to evaluate the effectiveness of current water and air
treatment techniques for the removal and control of potential' nanoscale pollution.
However, people must remain mindful of the potential ramifications of this
technology, including the fact that nanoscale materials can enter the food chain and be
absorbed or transported by water and food. Bioavailability and toxicity of newly created
nanoscale materials are largely unknown. Nanotechnology is highly interdisciplinary and
may present further challenges for environmental scientists and engineers.

1.3 Problem Definition
From the reports of pharmaceutical industry, it is said that, around 40% of the drugs
being developed by the industries are not soluble in water

[16 171
'

.

Hence, these drugs have

poor wetting properties and less ability to dissolve with gastrointestinal fluids. It is a
great challenge for the scientists to improve dissolution properties of the drug in older to
improve the bioavailability. According to the Noyes-Whitney equation, as the panicle
size decreases, its surface area increases and thus improves the dissolution properties

[181 .

There are many commercially used methods to reduce the particle size such as
mechanical comminution (crushing, milling, grinding, and jet milling), thermal
recrystallization, spray drying, freeze drying and recrystallization using solvent
evaporation etc. Techniques described above are associated with many drawbacks.
Mechanical comminution is simple and economical, but it is not able to accomplish
desired amount of particle size reduction and it is not suitable for thermally sensitive
compounds. Thermal recrystallization, spray drying methods requires using lot of
solvents. In addition, all these methods requires relatively high-energy and yet suffer
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from poor control in maintaining particle size, PSD and morphology

[191

.

Though Liquid

Anti solvent method is simple and economical technique for pharmaceutical industry,
there are some drawbacks such as uncontrolled growth and agglomeration of nano
particles after the formation and particle growth by Ostwald ripening. These limitations
affect the quality and stability of the drug. Nanoparticles can provide required surface
area improvement. However, production of particles at nanoscale ranges remains
challenging

[20, 21, 22].

1.4 Objectives
This research project focuses on production of ultrafine particles of Griseofulvin through
Liquid Anti solvent crystallization by using ultrasound nozzle and by using CO2.
Problems associated with Liquid Antisolvent process can easily overcome by using
ultrasound concentric nozzle. Ultrasound nozzle increases the nucleation rate and
decreases the particle agglomeration. Due to atomization created by the nozzle, both
solvent and antisolvent can be sprayed in the form of fine droplets. As a result, fine
particles can be precipitated. Use of surfactants and polymers can control the particle
size. Surfactants and polymers, reduce the surfacetension thereby increases the nucleation
rate. The process that uses CO2 can also produce ultrafine particles. When solution
containing CO2 is depressurized, CO2 evaporates from solution at normal atmospheric
pressure. Removal of latent heat from the solution reduces the solution temperature
causes supersaturation in solution. Supersaturation induces nucleation and initiates
precipitation process. Thus fine particles can be produced.

9
1.5 Organization of Thesis

In this thesis after the Introduction, Chapter 2 presents a review on production of
Ultrafine particles. Chapter 3 focuses on the selected methods used to produce nano
particles and materials used. Chapter 4 presents results and brief discussion on the
experimental work done. Chapter 5 presents conclusions based on the research and
suggestions for future work. Chapter 6 includes references.

CHAPTER 2
PROCESS FOR PRODUCTION OF ULTRAFINE PARTICLES-AN OVERVIEW

Over the decades, many particle production processes have been developed for use in
pharmaceutical industries. To enhance the properties of poor water soluble drugs,
nanoparticle production processes such as, mechanical micronization techniques,
supercritical fluid techniques, cryogenic spray processes, and solvent evaporation
processes have been developed.

2.1 Mechanical Micronization Techniques
Grinding and high pressure homogenization techniques are commercially popular
methods for reducing particle size. Dry grinding with media mill and jet mill limits the
particle size to few microns. Hence, wet grinding with ball media mill and liquid jet mill
came in to picture in late 1990's. There is some equilibrium between the particle size and
grinding time. Once the particle reaches its minimum size, with the increase in grinding
time particle size starts increasing due to particle agglomeration

[671 .

Homogenization

process uses high pressure to break down the particles in the suspension.

2.1.1 Wet Grinding
Grinding is an attrition process. In this process, grinding media moves against one
another and against the walls of the mill. Grinding at lower speeds gives fine particles but
longer milling times are required. Finer particles can be produced by using wet milling
techniques

[231 .

In the wet milling process, the poor water-soluble drug is dispersed in an

aqueous-based surfactant solution, and then the resulting suspension is wet milled with

10
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the grinding media. The amount of grinding media, stabilizer and the raw material used
may vary with the type of mill. These are the main important factors affecting the
efficiency of the mill and particle fineness. Usually grinding media fills about 30% to
50% of the volume of the mill chamber 1231 . High-energy-generated shear forces and the
forces generated during impaction of the milling media with the solid drug provide the
energy to crush the drug particles into nanometer size

[21, 24]

Main limitation of the wet

milling process is contamination of the drug by grinding media used

[251 .

During the

milling process, due to erosion of grinding materials product is contaminated. In addition
to that, wet milling is a batch process. There is batch-to-batch variation detected in the
quality of dispersion, processing times, drug crystallinity and particle size distribution.
Due to these variations, drug particle stability, powder flow properties, and efficiency of
delivery system are affecting. In some cases, milling over the days brings the risk of
microbiological problems, especially when performing the milling at lower temperature
(temperatures below 30 °C) or having dispersion media providing nutrition to bacteria.

2.1.2 High Pressure Homogenization
High pressure homogenization is the other mechanical micronization process for reducing
the particle size of poor water soluble drugs present in liquid suspensions. With this
method it is possible to make more stable suspensions for enhanced clinical effectiveness.
As the active ingredients are homogeneously distributed in the suspension, bioavailability
of the drug increases. In this method drug is dispersed in an aqueous solution by high
speed stirring to get a suspension. Obtained suspension is then passed through a high
pressure homogenizer through 3 to 20 cycles at a pressure of 1500 bar

[251 .

Then at the

same pressure, suspension passes through a very small homogenization gap having a
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width of 25 Due to its small width, dynamic fluid pressure increases with increase in
streaming velocity of the suspension. As a result, water starts boiling at room temperature
and cavitation occurs when fluid leaves the homogenization gap

1251 .

These cavitation

forces are strong enough to break the drug microparticles into drug nanoparticles

[25, 26]

Particles produced from this process have an average size of 40 nm to 500 nm, and
particles greater than 5 pm are less than 0.1% in the total population

[25, 261 .

The particle

size depends on the hardness of the drug substance, processing pressure and number of
cycles applied. Size can be controlled by adjusting the operating parameters like pressure
and cycles applied. Application of high pressures tends to give more amorphous particles.
The stabilization against aggregation and coalescence is the main challenge while
forming nanosuspensions. Stability of nanosuspensions can be determined by the zeta
potential. In addition to that, Ostwald ripening also determines the stability of highly
dispersed systems

[251 .

The absence of Ostwald ripening indicates the long-term physical

stability of an aqueous suspension

[In .

It was observed that there was no Ostwald

ripening in the nanosuspensions produced by high-pressure homogenization process.
Nano suspensions produced from this processes have less concentration differences,
which is a main prerequisite for commercial large-scale production from this process.
High-pressure homogenizers are available with different capacities from a few hundreds
to a few thousands liters per hour

[25, 26] .

One disadvantage of this process is that,

application of high pressures used can change particle crystallinity and batch-to-batch
variation in crystallinity level might be an issue for quality control. Stability of partially
amorphous nanosuspensions is the main challenge in pharmaceutical industry
applications.
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2.2 Supercritical Fluid [SCF] Technology
Since there are many disadvantages with high energy milling such as contamination and
batch variation etc, another alternative method to produce nano particles is, Supercritical
fluid technology. Supercritical fluids have higher viscosities and diffusivity coefficients
and are good solvents. Physical properties of Supercritical fluids (SCF) such as liquid like density, gas like diffusivity, negligible surface tension and liquid like viscosity can
be manipulated over a wide range by varying both temperature and pressure. There are
,

many advantages in selecting carbon dioxide from many Supercritical fluids as it has low
critical Temperature (Tc) = 31.1°C and moderate critical pressure (Pc) = 73.8 bar, and it
is nonflammable, nontoxic, and readily available in high purity. The basic principle of
Supercritical fluid technology is precipitation of micron and sub micron particles by rapid
depressurization of saturated solutions. Different SCF techniques such as Rapid
Expansion of Supercritical Solutions (RESS)
35]

[28 331

,

Supercritical Antisolvent (SAS)

and Depressurization of Expanded Liquid Organic Solutions (DELOS)

[36 - 38]

[34,

etc. are

being investigated.

2.2.1 Rapid Expansion of Supercritical Solutions (RESS)
In this process drug is dissolved in supercritical fluid which acts as a solvent. This
solution is depressurized through a nozzle, which has small orifice. The rapid expansion
of supercritical fluid solutions through the small orifice produces an abrupt decrease in
solubility of the solvent as it goes from a supercritical fluid state to a very low-density
gas phase after the expansion. This results in the nucleation of any low-vapor-pressure
solute species that were present in the solution prior to expansion. Controlled particle

14

size distribution and morphology mainly depends on the solubility of drug in supercritical
fluid, operating parameters (temperature and pressure), nozzle geometry and dimensions.

Extraction unit

Healing

Precipitation
chamber
Vent

Figure 2.1 Schematic diagram of RESS process. [67)

A solid co·so lvent can be added to increase the so lubility of drug, which has low

•

solubility in supercritical fluid . This process can be called as RESS-SC (Rapid Expansion
of Supercritical Solutions _. Solid Co-solvent). Later a solid co-solvent can be separated
from the drug by using different techniques like lyophilization etc. The main advantage
ofthis process is that it reduces the need for using harmful organic solvents. Though this
process is simple and easy to develop, there are many limitations like poor solubility of
many drugs in supercritical fluids, design of nozzle and scale-up problems involved in
this method

[28 - 33]
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2.2.2 Supercritical Antisolvent (SAS) Precipitation
In this process drug is dissolved in an organic solvent and this solution is sprayed through
a nozzle in to a high-pressure chamber. This chamber is filled with supercritical CO 2,
which acts as antisolvent. When the sprayed solution comes in contact with supercritical
CO 2, nucleation occurs by two way diffusion between supercritical CO 2 and the solution.
Controlled particle size distribution and morphology depends on operating parameters
(temperature and pressure) and nozzle dimensions. [34,35)

Nozzle I""Tlfn

High Pressure

Chamber
Vent

I 1:-1

L!.J
.
"

Solution

Separation
Tank

Figure 2.2 Schematic diagram of SAS process. [67]

2.2.3 Depressurization of Expanded Liquid Organic Solutions (DELOS)
In depressurization of Expanded Liquid Organic Solution (DELOS), super critical CO 2
acts as a co solvent for the formation of nano sized particles. The driving force behind
DELOS process is a fast and large temperature drop. This occurs when the pressurized
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solution is expanded from a working pressure (P

) to atmospheric pressure. This fast

drop in temperature causes the saturation limit to drop equally as fast causing the
crystallization of particles from the solution. In DELOS process, solute is dissolved in an
organic solvent in a pressure resistant chamber that is heated to a desired working
temperature. Once this is complete, SC CO2 is pumped to dissolve into the solution and
used to achieve the desired working pressure (P w).
w Sufficient time is provided for the
ternary solution to reach equilibrium and the working temperature (T w). Once
equilibrium is achieved, the solution is expanded through a one-way valve into a chamber
at atmospheric pressure. Pure nitrogen is pumped into the solution chamber to maintain
the working pressure during expansion. A filter at the bottom of the expansion chamber
collects the solute powder [37, 39] .
It has been shown that the DELOS process is not dependent on the pressure
change from the working pressure to atmospheric pressure. Ventosa, et al. [39] have
shown that for a given system yield, particle size, and particle size distribution are
dependent on the temperature drop from the working temperature to the final
depressurization temperature (TF), therefore the main factors that control yield are the
working concentration of CF and the initial solubility ratio 139] . This allows the process
to be carried out at lower temperatures without any effects 1391 . Since crystallization
through the (DELOS) process is dependent on a large temperature drop, the yield can be
maximized by maximizing the amount of SC CO2 used.

17

1
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Figure2.3 Schematic diagram of DELOS process P9]

The main advantage of (DELOS) is encapsulation. It is very cost effective and
nano powders formed from this process are of highest quality. The di sadvantage is,
solubility is limited and reaches saturation very fast and the particles formed are not in
spherical shape and needs to be treated by other techniques to produce spherical shapes,
which are costly (37,39]

2.3

Spray Process

Another method to produce micro and nano particles is cryogenic spray process. Sprayfreezing into vapor processes have been developed under cryogenic spray process.
Usually, in these processes, halocarbon refrigerants and liquid nitrogen have been used as
cryogenic media

(40· 51]

Generally, in these processes, drug solution is atomized through
.

,

'

the nozzle in a chamber that contains cryogenic media. Atomized droplets gradually
solidify and then freeze while they pass through the cryogenic media. A spray .. freezing
into vapor process has been developed by Gombotz el af and Gusman and Johnson
55]

[5 2-

In this process, atomization of drug solution takes place in nitrogen vapor. Solution
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droplets gradually solidify while passing through nitrogen vapor and freeze when they
come in to contact with cryogenic liquid 120] . There are some drawbacks like broad
particle size distribution and presence of non-micronized particles in this process. To
overcome this, a new cryogenic spray process has been developed and patented by The
University of Texas at Austin in 2001

[56]

and commercialized by The Dow Chemical

Company.

2.3.1 Spray Freezing into Liquid (SFL) Process
In this process, a solution that contains a drug is atomized through a nozzle in to a
compressed liquid. The compressed liquids used in this process are, compressed CO2,
helium, propane, ethane, or the cryogenic liquids including nitrogen, argon, or
hydrofluoroethers

[56] .

Nano particle formation is due to intense atomization of drug

solution and then rapid freezing in the cryogenic liquid medium. High degree of
atomization occurs by spraying drug solution directly in to cryogenic liquid and rapid
freezing is achieved by low temperature provided by cryogenic liquids and formation of
high surface area droplets. The high degree of atomization and rapid freezing rates led to
formation of amorphous nanostructured particles with high surface areas, enhanced
wetting and significantly enhanced dissolution rates

[20, 57, 58 - 664

] According to the need,

obtained nano particles in the liquid medium are dried in lyophilizer to get dry powder.
Powders produced from SFL process exhibits higher dissolution rates compared to the
micronized bulk drugs. Powders produced from this drug can be used for different
delivery systems such as respiratory delivery, oral delivery etc.
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2.4 Solvent Evaporation Process
Two solvent evaporation techniques used for production of nano particles are described
below. In both techniques, drug is dissolved in a solvent and then the solution is sprayed
through the nozzle into a chamber. Nanoparticles are formed by the evaporation of
solvent.

2.4.1 Spray Drying
Spray drying is a common method used in many pharmaceutical industries. In this
method, typically, drug solution is pumped through a nozzle and is atomized in a
chamber containing a hot gas. Production of Nano particles of sensitive materials requires
oxygen free drying and hence nitrogen gas is used instead of hot gas. Different types of
atomizers are used for spray drying such as, single fluid, two-fluid, and ultra-sonic
designs. These different styles have different advantages and disadvantages depending on
the application of the spray drying required.
Spray drying process is used by food and pharmaceutical industries as an
encapsulation technique. Dehydrated powders such as instant drink mixes are produced
by this technique. This technique is mainly used in food industries for the preparation of
dehydrated milk. As this process causes thermal degradation, other techniques are used
for the milk dehydration. Skim milk powder is still widely produced using spray drying
technology around the world, typically at high solid concentration for maximum drying
efficiency. Thermal degradation of products can be overcome by using lower operating
temperatures and larger chamber sizes for increased residence times.
Recent research is now suggesting that the use of spray-drying techniques may be
an alternative method for crystallization of amorphous powders during the drying process
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since the temperature effects on the amorphous powders may be significant depending on
drying residence times.

2.4.2 Evaporative Precipitation in to Aqueous Solution (EPAS)
This process was developed and patented by The University of Texas at Austin and
licensed to The Dow Chemical Company in 2001. In this process, drug is dissolved in an
organic solvent and is sprayed through a nozzle at high pressures and temperatures.
Usually temperatures maintained are above the boiling points of the organic solvent and
nozzle is placed in a heated aqueous solution. Nozzle is immersed in aqueous solution to
avoid the crystal growth. According to need, stabilizers are added to organic solution and
aqueous solution. Drug nano particle suspension is dried by using lyophilizer or spray
dryer. There are many advantages with EPAS process over spray drying process. In
EPAS Nanoparticles are formed due to rapid evaporation of the heated organic solution
and fast nucleation. Varieties of hydrophilic stabilizers are found in order to control the
particle size. These stabilizers work by diffusing to the surface of growing particles
rapidly enough in order to prevent the particle growth.
When hydrophilic surfactant is used, it migrates towards the drug-water interface
during particle formation, and the hydrophilic segment is oriented outwards towards the
aqueous continuous phase. The stabilizer inhibits crystallization of the growing particles
[65] In spray drying process, this type of hydrophilic surfactant coating is not possible
because of absence of water. Even after the solution is dried to form powder, hydrophilic
surfactant is surrounded by drug. As a result of this dissolution rate of the drug increases.
To prevent the agglomeration and particle growth, high surfactant adsorption levels on
the surface of the particle are required. Applications of EPA .S suspensions include, use in

21
parenteral formulations to enhance the bioavailability and in oral dosage forms. The
ability to engineer stable particles with high potencies and high dissolution rates with
EPAS presents new opportunities in the development of commercial formulations for
poor water-soluble drugs.

2.5 Comments
In summary, recent advances in commercially or potentially commercially available
nanoparticle engineering processes have been discussed. These nanoparticle engineering
processes including wet milling, high pressure homogenization, RESS, SAS, DELOS,
SFL, Spray drying and EPAS techniques have successfully incorporated poorly water
soluble drugs alone, or with excipients into the microparticles or nanoparticles with
significantly improved dissolution rates and bioavailability. As the percentage of poor
water-soluble experimental compounds is increasing, nanoparticle-engineering processes
for enhancement of dissolution rates of poorly water-soluble drugs offer great promise for
pharmaceutical development and manufacturing to bring these experimental compounds
into the market.
Though there are many processes available in the literature, precipitation of
ultrafine fine particles of active pharmaceutical ingredients with low water solubility is
still a difficult task. Inspite of all the available processes, Liquid antisolvent (LAS) is still
a commercially viable and economically attractive process. In current research work,
Liquid antisolvent process is used to produce ultrafine particles.
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2.6 Liquid Antisolvent (LAS)
Liquid antisolvent techniques have been using in many industries to crystallize solid
compounds. As this technique eliminates the use of thermal energy which can lead to the
degradation of biological activity of drug particles, it has become one of the most
promising particle production techniques in the pharmaceutical industry. In the most
common procedures, a poor solvent of a particular drug is added to the drug solution in
order to precipitate the solute. Water is most commonly used as an antisolvent for
hydrophobic drug compounds, whereas organic solvents are used for hydrophilic
compounds. Drug is precipitated upon mixing of solution and antisolvent. The working
principle behind this technique is that during mixing, there is an increase in the molar
volume of the solution that results in decrease in solubility power of the drug and hence
the precipitation. Even though it has been widely used in industry, there is minimal
control over the crystal morphology and size distribution. A combination of surfactants
and ultrasound is used in order to control the particle size and distribution.

CHAPTER 3
MATERIALS AND METHODS

3.1 Materials
3.1.1 Drug
O6
The drug Griseofulvin with molecular formula C 17H
17

is an antifungal antibiotic. It is

derived from a species of Penicillium. It is used in the treatment of ringworm and other
fungal infections of the skin or nails.

Figure 3.1 Griseofulvin structure.

Some research shows that it can be used to treat cancer as it inhibits the cell
division in cancer cells. It does not interfere with cell division in healthy cells. ≥ 95%
(HPLC grade) is purchased from Sigma Aldrich and is used without any further
purification. Griseofulvin is poorly soluble in water but is soluble in many organic
solvents such as acetone, DCM, DMF, ethanol and Triacetin.
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3.1.2 Solvents
Solvents Acetone (CHROMASOLV®, for HPLC, ≥ 99.8%) and DCM
(CHROMASOLV®, for HPLC, ≥ 99.9%) were purchased from Sigma Aldrich and were
used without any further purification.

Figure 3.2 Acetone and DCM.

Acetone is an organic solvent with the formula CH 3COCH3 and is miscible with
water. Dichloromethane (DCM) is the chemical compound with the formula CH .2C1Itis
a colorless, volatile liquid widely used as a solvent for many chemical processes. It is
miscible with most organic solvents and immiscible with water. Griseofulvin solubility in
acetone is 38 mg/ml and in DCM is 0.220 gm/ml.

3.1.3 Surfactants
Surfactants Tween 80 (viscous liquid with average molecular weight 1310 and the
composition of Oleic acid and ~70% (balance primarily linoleic, palmitic, and stearic
acids)), Sodium Dodecyl Sulphate (Sigma Ultra, ≥99.0% (GC)) and Poloxamer 188 (a
solid contains 100 ppm BHT with average molecular weight 8350) are purchased from
Sigma Aldrich and are used without any further purification.
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Figure 3.3 Tween-80, SDS, Poloxamer 188.
Tween 80 is a nonionic surfactant and emulsifier often used in ice cream to
prevent milk proteins from completely coating the fat droplets. It is also known as
Polysorbate 80. It is a viscous, water-soluble yellow liquid. Tween 80 can be used as an
emulsifier in the manufacture of medications for parenteral administration. Its CMC is
around 1.2* 10-5 Mat 25°C.
Sodium Dodecyl Sulphate is an anionic surfactant with molecular formula
C12H25SO4Naisuednholprctsuaohe,mpsaving
foams, some dissolvable aspirins, fiber therapy caplets etc. The molecule has a tail of 12
carbon atoms, attached to a sulfate group, giving the molecule the amphiphilic properties
required of a detergent. It is a smaller molecule as compared to Tween 80 and its CMC is
around 0.0082 M at 25°C.
Poloxamer is a triblock copolymer. It has two hydrophilic polyethylene oxide
ends and one hydrophobic polypropylene oxide segment in the middle. They can be used
to increase the water solubility of hydrophobic, oily substances or otherwise increase the
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miscibility of two substances with different hydrophobicities. For this reason, these are
commonly used in industrial applications, cosmetics, and pharmaceuticals. They have
also been used as model systems for drug delivery applications. Its CMC is 0.0004 M at
25°C.

3.1.4 Polymers

Figure 3.4 HPMC, PVP, Polymer JR.
Polymers HPMC, PVP (average mol wt 360,000) and Polymer JR are purchased from
Sigma Aldrich and are used without any further purification.
Hydroxy Propyl Methyl Cellulose (HPMC) is a semisynthetic, inert, viscoelastic
and non - ionic water-soluble polymer. It is used as an ophthalmic lubricant, excipient
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and controlled-delivery component in oral medicaments. In oral tablet and capsule
formulations, it is used to delay the release of a medicinal compound into the digestive
tract.
PVP is a non ionic polymer and is soluble in water as well as other polar solvents.
It is as an inhibitor of recrystallization and increases the solubility of drugs in liquid and
semi-liquid dosage forms (syrups, soft gelatin capsules etc). PVP in its pure form can be
edible by humans. Main applications include binder in many pharmaceutical tablets,
stabilizer in food additives, used in personal care products such as shampoos and
toothpastes, in paints, and adhesives like old-style postage stamps and envelopes etc.
PVP added to Iodine forms a complex (Povidone - iodine) that possesses disinfectant
properties. This complex is contained in various products like solutions, ointment, liquid
soaps and surgical scrubs.

3.2 Methods
3.2.1 Experimental Methods
Two methods, Liquid antisolvent precipitation by using ultrasonic nozzle and MDELOS,
are developed for the production of nano particles.
3.2.1.1 Liquid Antisolvent Precipitation using Ultrasonic Nozzle.

In many

pharmaceutical industries, liquid antisolvent technique is used for the production of nano
particles. Since many of the drugs used in the pharmaceutical industry are thermally
sensitive and poorly water-soluble, this technique is more suitable for the production of
nano particles. In this technique typically, a poor solvent of a particular solute is added to
the solution in order to precipitate the solute. When the solution and antisolvent are
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mixed together, precipitation occurs. The most common antisolvent used for this
technique is water when poorly water-soluble drugs are being precipitated. The working
principle behind this technique is that during mixing, there is an increase in the molar
volume of the solution that results in decrease in solubility power of the solute and hence
the precipitation. Though these techniques are widely used in industry, these are also
associated with some drawbacks such as, controlled particle size distribution and
morphology.
Liquid antisolvent precipitation using ultrasonic nozzle involves three steps for
the production of nano particles. Figure 3.5 schematically shows the steps involved.

Figure 3.5 Flow diagram of Liquid anti solvent process with ultrasonic nozzle.
Solution of a drug in the solvent is prepared. The power of ultrasound unit applied
to the nozzle is set in order to atomize the solution coming from pumps. Atomized
solution is directly collected in a chamber containing water with stabilizers. The
concentric ultrasonic nozzle consists of inner nozzle with ID of the nozzle is 0.5 mm and
the outer nozzle with OD of 1.00 mm. Nozzle length is 6.5cm. Maximum nozzle power is
20watts. Capacity of collection chamber is 250m1. Pumps can pump liquids up to
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200ml/min. Solvent pump's connection goes to inner nozzle and water pump's
connection goes to outer nozzle. Different stabilizers such as surfactants, polymers and
electrolytes are added either in solvent or in water or in both. The apparatus used at New
Jersey Institute of Technology is shown schematically in Figure 3.6.

Figure 3.6 Schematic diagram for Liquid Antisolvent method with ultrasonic nozzle.

3.2.1.2 Precipitation of Ultrafine Particles using Subcritical CO 2.

In this

process, CO2 acts as a co solvent for the formation of nano sized particles. Nano particles
are formed due to large temperature drop caused by CO 2 expansion from working
pressure to atmospheric pressure. Due to large drop in temperatures, solubility of the drug
in the solution decreases and eventually drug particles are precipitated in the collection
chamber, which is at atmospheric pressure. This is very simple technique. There are only
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four steps involved for the production of nano particles. A simple flow diagram of the
process is shown below.

Figure 3.7 Flow diagram of precipitation of ultrafine particles using subcritical CO

2

Process

The first step in this process is the preparation of the supercritical solution. The
solution consists of supercritical solvent and a solute (drug / API). A liquefied solvent, at
conditions higher than Tc and Pc, is pumped from the cylinder to an extraction chamber.
The dissolution of solute in the supercritical solvent takes place in the extraction
chamber. The dissolution properties of the solute depend on the extraction conditions
(temperature and pressure) as well as the chemical characteristics of the solute.
Therefore, it is essential to determine the solute solubility in supercritical solution
through experiments or literature review. Required apparatus includes compressed CO 2
cylinder, extraction chamber, expansion chamber and nozzle. Both expansion and
extraction chambers should be high-pressure vessels. Detailed procedure of conducting
experiment is described below. The apparatus used at New Jersey Institute of Technology
is shown in Figure 3.8.
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Figure 3.8 Schematic diagram for process using subcritical CO2 for precipitation of
ultrafine particles.

Drug is dissolved in solvent and then fed to extraction chamber. Surfactant is
added to the solvent if required. Extraction chamber is closed and filled with supercritical
CO 2 at desired pressure. Allow some time to achieve equilibrium between the CO2 and
solvent. Depressurize the solution by opening the valve. Expansion chamber is filled with
water. After depressurization, CO 2 evaporates from expansion chamber.

3.2.2 Characterization Techniques
Characterization of the particles precipitated using the above-described processes has
been performed using scanning electron microscopy and Light scattering technique.
3.2.2.1 Scanning Electron Microscopy (SEM). SEM is used to observe the
morphology of the particles. Scanning Electron Microscopy (SEM) is a very useful tool
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for characterization of ultrafine particles. Images were taken using a Scanning Electron
Microscopy (LEO 1530VP (FESEM-EDS) / Zyvex Nanomanipulator System) at an
accelerating voltage ranging from 5 to 10 KV. The sample was deposited on a silicon
chip fixed on aluminum stub. Liquid solution obtained from the experiment was
sonicated for 30 minutes and few drops from this solution are deposited on the stub to
analyze on SEM. The stub was then placed under vacuum in order to remove the
moisture from the sample. Stubs must be completely dry in order to analyze them under
SEM. SEM micrographs from different regions of the stubs were obtained.
Multiple images for each experiment were processed in order to get a proper
representation of the particles. Several results obtained using SEM was compared with
light scattering (where available) results and were found to be significantly similar.

3.2.2.2 Beckman Coulter - LS 230.

Light scattering (Beckman Coulter LS 230)

is the most sophisticated particle size analyzer with 132 optical detectors. The LS uses
reverse Fourier lens, which enables it to optimize light scattering across the widest
dynamic range in a single scan. It is used to measure hydrodynamic diameter of aqueous
solution of drug and milli-Q water. Polarization Intensity Differential Scattering (PIDS)
was also performed using Fraunhofer diffraction model. Range of particle size that can
be analyzed is 0.04 μm to 2000 lam. Samples were first sonicated for 30 minutes and then
used for analyzing.

CHAPTER 4
RESULTS AND DISCUSSION

Experiments were conducted to study the effect of operating parameters on the particle
size, particle size distribution and morphology for Liquid Antisolvent process by using
ultrasonic nozzle. Experiments are conducted by varying drug concentration, nozzle
power, solution and solvent flowrate. Surfactants and polymers are added to water to
stabilize and control the particle size. The following sections describe effects of varying
different parameters.

4.1 Initial Screening of Process Parameters
Table 4.1 Effect of Operating Parameters and Surfactant
Exp

Power
(watts)
(wa

Water
Flowrate
(ml/min)

T-80
-80
(CMC)

so Bath
nication

Mean
particle size
(lm)

SD

1

0

0

0

No

23.18

9.85

2

0

0

5

No

14.88

7.89

3

10

0

5

No

13.26

5.27

4

10

0

5

Yes

11.47

4.32

5

10

2

5

Yes

11.09

2.14

Experiment 1, is a simple liquid antisolvent process in which solution of the drug and the
solvent is added to an antisolvent to precipitate the drug particles. Precipitated particles
are about 23 microns size. In order to study the effect of surfactant, experiment 2 was

33

34
conducted by adding the Tween 80 (5 CMC) in the water used in collection chamber. At
these experimental conditions, mean particle size of precipitated particles was around
14.9 microns. Addition of surfactant reduces the surface tension, increases the nucleation
rate and also reduces the agglomeration. In order to study the effect of atomization,
experiment 3 was conducted by applying power to nozzle. When the atomized droplets of
solution came in contact with antisolvent, drug particles were precipitated. The particle
size obtained is 13.26 microns. Application of ultrasonic nozzle atomizes the droplets and
hence reduces the particle size.
The precipitated particles were collected in water in a collection chamber. As
Griseofulvin is hydrophobic, the precipitated particles agglomerate in water. Therefore,
in experiment 4 particles were collected in sonicated water using a bath sonicator.
Particles produced were smaller than the particles formed from previous experiments due
to the prevention of agglomeration. In experiment 5 both drug solution and water were
pumped through a concentric nozzle vibrating at the tip. Vibrations due to ultrasound
enhance the micro mixing of antisolvent and solution streams and increase the nucleation
rate. This further decreases the particle size.
As it is seen that the process parameters affect the particle size and its
distribution, it was therefore decided to generate DOE to identify important process
parameters. Next section describes the DOE for liquid antisolvent experiments with
ultrasonic concentric nozzle.
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Figure 4.1 SEM micrographs for the experiments shown in Table 4.1.
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4.2 Full Factorial Experiment by using DOE
Full factorial experiments were designed by using Minitab software. For full factorial
design, three factors such as, concentration of the drug in the solvent, power applied to
the nozzle and flowrate of antisolvent were considered. In this design, three levels were
considered for each factor. Values for concentration were 0.01, 0.05 and 0.09, values of
power were, 0, 5 and 10 and values for flowrate were, 0, 5 and 10. By following the
DOE, total 27 experiments were conducted in a random order and the results are
tabulated in Table 4.3. Procedure followed for conducting these experiments is described
below.
The given amount of drug is dissolved in 10 ml of solvent. Power and water flow
rate were adjusted as required. 200 ml of water along with surfactant Tween-80 was
taken in the collection chamber. Concentration of Tween-80 was 5 CMC. For all these
experiments, flowrate of drug solution was fixed at 2 ml/min. After each experiment,
collected samples were analyzed using light scattering and SEM.

Table 4.2 Analysis Of Variance (ANOVA) Table
Source

DF

Seq SS

Adj SS

Adj MS

F

P

C

2

1111.118

1111.118

555.559

13.62

0.032

P

2

104.268

104.268

52.134

1.34

0.388

W

2

179.981

179.981

89.991

1.67

0.3

C*P

4

93.702

93.702

23.425

1.12

0.411

C*W

4

153.15

153.15

38.288

1.83

0.216

P*W

4

145.862

145.862

36.466

0.233

C*P*W

8

167.333

167.333

20.917

1.74
**

Error

0

*

*

*

Total

26

1955.415
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Table 4.3 Full Factorial Design to find out the Significant Factor

Exp
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Drug weight
(g)
0.09
0.05
0.05
0.09
0.05
0.05
0.09
0.01
0.01
0.05
0.05
0.09
0.01
0.01
0.09
0.09
0.05
0.05
0.09
0.05
0.01
0.01
0.01
0.09
0.09
0.01

Power
(W)
10
5
0
0
0
10
5
0
10
10
0
10
5
10
5
10
10
5
5
5
5
5
0
0
0
0

Water flow
(ml/min)
10
0
5
0
10
0
0
10
10
5
0
5
10
0
10
0
10
10
5
5
0
5
5
10
5
0
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0.01

10

5

Water
Size
Collection
(microns)
(ml)
10.19
300
15.1
200
10.02
250
28.61
200
13.27
300
11.61
200
22.6
200
12.86
300
6.114
300
17.33
250
22.56
200
30.19
250
300
7.4
11.5
200
13.65
300
11.5
200
8.66
300
300
11.91
250
18.53
17.93
250
200
2.97
7.47
250
6.43
250
24.89
300
250
29.65
12.51
200
250

8.479

S.D.
5.67
4.35
5.93
20.47
8.55
6.94
12.51
6.47
2.99
12.16
15.44
20.57
3.05
9.4
11.48
9.4
3.32
6.28
11.95
12.34
1.84
3.79
3.15
8.04
18.31
6.52
2.93
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For this full factorial design experiment, ANOVA is conducted for the mean
particle size. From the Table 4.2, it is clear that, concentration had significant effect on
the particle size. Therefore, experiments were conducted by varying the concentration of
Griseofulvin in acetone to study the concentration effect on the particle size, size
distribution and morphology.

4.3 Effect of Concentration on the Particle Size
Table 4.4 Effect of Concentration on the Particle Size
Exp

Conc.
(gm/ml)

Power
(watts)

Mean
(μm)

Median

Mode

S.D

D10

D50

D90

1

0.005

10

10.2

8.8

10.3

5.7

4

8.8

19.2

2

0.01

10

7.6

6.2

7.8

5.5

2.2

6.2

15

3

0.015

10

8.08

7.15

9.37

5.01

2.57

7.15

14.7

4

0.02

10

8.29

7.02

9.37

5.76

2.29

7.02

15.7

5

0.025

10

9.03

7.53

9.89

6.45

2.34

7.53

17.6

6

0.03

10

9.64

7.98

10.3

7.01

2.51

7.98

18.7

7

0.035

10

12.1

9.88

11.3

8.52

3.45

9.88

24.3

8

0.04

10

13.9

11.5

12.4

9.28

4.38

11.5

27.1

Table 4.4 and Figure 4.2 show the effect of concentration on the particle sizes and size
distribution. It is observed that needle like bipyramidal particles were precipitated at all
concentrations.
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Figure 4.2 Effect of concentration on the particle size.
From experiments 2 to 8, particle size increased with increasing concentration of
the drug. At lower concentration like 0.005 gm/ml, particle size was smaller than at other
concentrations. The particle size goes through the minimum with change in
concentration. At higher concentrations, there will be higher driving force for particle
growth and increase in agglomeration increases the particle size. At lower concentration,
there will be low supersaturation and lower nucleation rate increases the particle size.

Figure 4.3 SEM micro graphs for the experiments 1, 4, 6 and 8 shown in Table 4.4.

....
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4.4 Effect of Surfactant on the Particle Size
Surfactants reduce the surface tension of solution and there by increase the nucleation
rate of precipitating solute. Surfactants stabilize the particle size by their specific
adsorption- on to the particle surface. Experiments have been carried out by adding
surfactant in antisolvent phase and in organic phase separately.

4.4.1 Surfactant in Antisolvent Phase
Table 4.5 Effect of Surfactant (0.7 CMC) on the Particle Size when Surfactant is added
in the Water
Exp.

Conc.
(gm/ml)

Surfactant

Power
(watts)

Mean
(μm)

SD

D10

D50

D90

1

0.01

Tween 80

10

10.2

7.94

3.2

7.63

21.7

2

0.01

Poloxamer 188

10

8.67

5.96

3

7.05

16.4

3

0.01

SDS

10

6.37

4.64

2.2

5.07

12

Table 4.5 and Figure 4.5 show the effect of surfactant on particle size and particle size
distribution. It can be seen that anionic surfactant SDS can control particle size and
particle size distribution better than other surfactants. Adsorptions of anionic molecules
of SDS on the particle surface develop negative charge on the surface of the particles and
hence effectively control the agglomeration.
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Figure 4.6 SEM micrographs for the experiments 1 and 3 shown in Table 4.6.

-
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Figure 4.5 Effect of surfactant on the particle size.
4.4.2 Surfactant in Organic Solution Phase
Table 4.6 Effect of Surfactant (0.7 CMC) on the Particle Size when Surfactant added in
the Solvent
Exp

Drug Conc.
(gm/ml)

Surfactant

Power
(watts)

Mean
(µm)

SD

D10

D50

D90

1

0.01

Tween 80

10

10.5

7.17

3.6

8.48

20.2

2

0.01

SDS

10

*

*

*

*

*

3

0.01

Poloxamer
188

10

9.14

6.67

3.4

7.23

16.9

SDS cannot be dissolved in acetone and hence the data is not reported for such a
condition. Comparison of Tables 4.5 and 4.6 shows that there is no much difference
between the particle size with change in location of the surfactant.
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4.5 Effect of Polymer on the Particle Size
Table 4.7 Effect of Polymer on the Particle Size
Exp

Polymer
weight. (gm)

Polymer

Power
(watts)

Mean
(μm)

SD

D10

D50

D90

1

0.01

HPMC

10

5.51

3.47

2.01

5.23

6.91

2

0.05

HPMC

10

9.47

7.95

3

3

0.1

HPMC

10

10.6

7.68

3.5

8.38

20.6

4

0.01

PVP

10

7.5

5.66

3.72

6.51

12.92

5

0.05

PVP

10

14.63

11.1

3.59

11.2

33.15

6

0.1

PVP

10

15.07

9.68

7.56

17.15

32.5

7

0.01

Polymer JR

10

6.24

3.29

2.6

5.55

11

8

0.05

Polymer JR

10

6.37

4.08

2.4

5.29

11.8

9

0.1

Polymer JR

10

7.91

5.71

2.6

6.4

14.8

I

6.84 21.5

Table 4.7 and Figure 4.7 shows that Polymer JR can control the particle growth better
than HPMC and PVP. PVP has only one carboxyl group and can not form hydrogen
bonds with the functional groups on Griseofulvin and hence is a poor candidate for the
control of particle growth and hence the agglomeration and particle size. Cellulosic
Polymers like HPMC and Polymer JR perform better than PVP as they have lots of
hydroxyl group present in a molecule and can form hydrogen bonds.
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Figure 4.7 Effect of polymer on the particle size.

4.6 Effect of Polymer and Surfactant Combination on the Particle Size
Table 4.8 Effect of Polymer and Surfactant Combination on the Particle Size
Drug
Conc.
(gm/ml)

Polymer +
Surfactant

Power

Mean

Exp

(watts)

(µm)

1

0.01

Polymer JR+SDS

10

2

0.01

HPMC+SDS

3

0.01

PVP+SDS

SD

D10

D50

D90

8.209

5.96

2.65

6.53

16

10

7.91

6.85

2.69

6.56

13.71

10

6.89

5.78

3.78

6.01

14.8

In order to study the effect of polymer and surfactant combination, 0.01 gm of SDS was
added to 0.01gm of polymer and was used for conducting the experiments. Table 4.8 and
Figure 4.9, show the effect of polymer and surfactant combination on the particle size and
size distribution.

Figure 4.8 SEM micrographs for the experiments shown in Table 4.8.
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Figure 4.9 Effect of polymer and surfactant.

If polymer alone was used, HPMC was giving smaller particles than PVP. But by
adding surfactant to the polymer, combination of PVP and SDS was giving better results
than the combination of HPMC and SDS. and Polymer JR and SDS. This is probably
because the interaction between PVP and SDS is stronger than the interaction between
SDS and HPMC or between SDS and Polymer JR. Because of this stronger interaction,
SDS adsorption on PVP chains is more as compared to HPMC and Polymer JR and hence
the PVP chains get straitened out more than HPMC or Polymer JR. Therefore PVP now
can control the particle growth better than Polymer JR or HPMC.
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4.7 Effect of Polymer, Surfactant and Electrolyte Combination on the Particle Size
Table 4.9 Effect of Polymer, Surfactant and Electrolyte Combination on the Particle
Size
Drug

Polymer+

Power

Mean

Conc.

Surfactant+

(watts)

(μm)

SD

D10 D50

D90

(gm/ml)

Electrolyte

1

0.01

Polymer JR 4- SDS + NaCl

10

9.741

7.53

2.84 7.49

19.83

2

0.01

HPMC + SDS + NaCl

10

8.45

6.35

3.62

8.3

14.12

3

0,01

PVP+ SDS + NaCl

10

2.02

1.07

1.17

1.72

3.19

Exp

In order to study the effect of polymer, surfactant and electrolyte combination, 0.01 gm
of SDS and 0.01 gm of NaCl was added to 0.01gm of polymer and was used for
conducting the experiments. Table 4.9 and Figure 4.11 show the effect of polymer,
surfactant and electrolyte combination on the particle size and size distribution. If
polymer alone is used, HPMC is giving smaller particles than PVP. By adding surfactant
to the polymer, combination of PVP and SDS is giving better results than combination of
HPMC and SDS. By adding electrolyte to all polymer and surfactant combinations, PVP,
SDS and NaCl combination is giving smaller particle size than other combinations. By
adding NaCl, particle size is drastically reduced for the combination of PVP, SDS.

Figure 4.10 SEM micrographs for the experiments conducted in Table 4.9.
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Figure 4.11 Effect of polymer, surfactant and electrolyte combination.

Addition of electrolyte NaCl to the solution enhances the interaction between
PVP and SDS. Na + ions get adsorbed on the PVP chain and hence PVP behaves as a
pseudo — poly cation. The negatively charged head group of SDS gets easily adsorbed on
to the chain because of electrostatic interactions. This helps in straightening of an
entangled polymer chain which now can better control the particle growth and reduce the
particle size and size distribution.
Results tabulated in Table 4.10 were taken from Tables 4.7, 4.8 and 4.9, in order
to study the effect of additives on particle size and size distribution. Experiments are
conducted by adding polymer, combination of polymer and surfactant and combination of
polymer, surfactant and electrolyte in antisolvent separately.
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Table 4.10 Effect of Additives on the Particle Size
Exp

Conc.
(gm/ml)

Additives

Power
(watts)

Mean
(p.m)

SD

D10

D50

D90

1

0.01

HPMC

10

5.51

3.47

2.01

5.23

6.91

2

0.01

PVP

10

7.5

5.66

3.72

6.51

12.92

3

0.01

Polymer JR

10

6.24

3.29

2.6

5.55

11

4

0.01

HPMC+SDS

10

7.91

6.85

2.69

6.56

13.71

5

0.01

PVP+SDS

10

6.89

5.78

3.78

6.01

14.8

6

0.01

Polymer JR+SDS

10

8.209

5.96

2.65

6.53

16

7

0.01

HPMC+SDS+NaCl

10

8.45

6.35

3.62

8.3

14.12

8

0.01

PVP+SDS+NaCl

10

2.02

l.07

1.17

1.72

3.19

9

0.01

Polymer JR + SDS
+ NaCl

10

9.741

7.53

2.84

7.49

19.83

Table 4.10 and Figure 4.13 shows that, by adding SDS to HPMC, particle size
increasing. Further addition of NaCl to HPMC and SDS, particle size is even bigger. In
contrast, for PVP addition of SDS and NaCl reduces the particle size and distribution.

..
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Figure 4.12 SEM micrographs for the experiments I and 4 shown in Table 4.10.
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Figure 4.13 Graph showing effect of polymer, surfactant and electrolyte combinations.
The above experimental results show that if a polymer alone is added, HPMC is
giving better results than PVP. Experiments 1, 2 and 3 in the Table 4.10, clearly indicate
that HPMC is giving better results with no addition of surfactant and electrolyte.
However, experiments 4, 5 and 6 show that PVP is giving better results with the addition
of surfactant SDS and electrolyte NaCl. Comparing all the experimental results from
Table 4.10, it is clear that combination of PVP, SDS and NaCl gives the narrowest
particle size distribution.
From above experiments it was observed that, by using PVP it was possible to
obtain smaller particles. To find out the size range of particles at saturated concentration
of Griseofulvin in antisolvent, following experiments were conducted.
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Table 4.11 Effect of Polymer, Surfactant and Electrolyte at Concentration 0.04 gm/ml
Exp

Conc.
(G/ML)

Additives

Power
(watts)

Mean
(μm)

SD

D10

D50

D90

1

0.04

PVP

10

10.3

7.2

2.93

8.61

19.81

2

0.04

PVP+SDS

10

4.15

2.96

1.61

3.34

7.86

3

0.04

PVP+SDS+NaCl

10

3.75

2.69

1.52

2.82

6.88

If experiments 4, 5 and 6 in Table 4.10 and experiments in Table 4.11 are
compared, with increase in drug concentration, particle size is increasing. In both tables
4.10 and 4.11, experiments done with PVP, SDS and NaCl, with increase in
concentration there is not much increment in particle size. To avoid using more solvent,
experiments can be conducted at higher concentrations if the obtained size is acceptable.

Figure 4.14 Effect of Polymer, Surfactant and Electrolyte at Concentration 0.04 gm/ml.

Figure 4.15 SEM micrographs for the experiments shown in Table 4.11.
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Table 4.12 Concentration of Components in Aqueous Suspension
Component

gm

wt%

0.4_

0.16

Solvent

7.85

3.05

water

249

96.77

HPMC

0.01

0.004

PVP

0.01

0.004

Polymer JR

0.01

0.004

Tween 80

0.01

0.004

SDS

0.01

0.004

Poloxamer 188

0.01

0.004

NaCl

0.01

0.004

Drug
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4.8 Precipitation of Ultrafine Particles using Subcritical CO2
In this method Griseofulvin is dissolved in organic solvent and the prepared organic
solution is pressurized with CO 2 . After allowing CO and organic solution to equilibrate
for 30 minutes, solution is depressurized through a valve in water containing stabilizers
such as Tween 80. Depressurization of solution containing dissolved CO causes
evaporation of CO from solution. Removal of latent heat of vaporization from the
solution, reduces the solution temperature. This generates super saturation in solution due
to reduction in equilibrium solid solubility in solvent induces nucleation and initiates the
precipitation process. Presence of surfactant in water controls the particle growth and
agglomeration by adsorbing on to the particle surface. Light scattering and SEM was
used to characterize the precipitated particles. Effect of process parameters such as initial
pressure, concentration and solvent characteristic have been studied on particle size and
distribution.

4.8.1 Effect of Concentration on the Particle Size
Following experiments were conducted in order to study the effect of concentration, with
different solvents, on the particle size. Experiments were conducted at different
concentrations by maintaining all other conditions constant. From the results shown in
Table 4.13 and figure 4.14, it was found that increasing drug concentration resulted in
larger particles and broader size distribution. Same trend was observed in the particle size
even with a different solvent.
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Table 4.13 Effect of Concentration on the Particle Size

Exp

Pressure
(bar)

Solvent

Temp
CC)

Conc.
(gm/ml)

Size
(μm)

SD

1

55

Acetone

26

0.001

5.37

3.2

2

55

Acetone

26

0.005

8.18

3.68

3

55

Acetone

26

0.01

9.1

5.32

4

55

Acetone

26

0.02

15.07

9.66

5

55

DCM

26

0.001

3.68

0.9

6

55

DCM

26

0.005

5.87

5.53

7

55

DCM

26

0.01

7.24

1.75

8

55

DCM

26

0.02

8.49

2.21

Figure 4.16 Effect of concentration on the particle size.
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Figure 4.17 SEM micrographs for the ex pf'rirnenls shown in Table 4. 13.
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From the above results, it was clear that lower concentrations can make particles
with narrow size distribution. For this process, along with drug concentration, particle
size also depends on operating parameters like pressure and the solvent chosen.

4.8.2 Effect of Solvent on the Particle Size
Table 4.14 Effect of Solvent on the Particle Size

Exp

Conc.
(gm/ml)

Solvent

Size
(μm)

SD

1

0.003

Acetone

7.62

5.05

2

0.003

DCM + Acetone

6.23

5.49

3

0.003

DCM

1.97

1.94

Solubility of Griseofulvin in DCM is higher than the Griseofulvin solubility in acetone.
Solubility of CO2 is higher in DCM than in acetone as DCM being non polar and acetone
being polar aprotic, higher CO2 dissolution causes more temperature drop and therefore
higher supersaturation is generated when DCM is used as solvent. Higher supersaturation
generates higher nucleation rate and hence particle size decreases.

Figure 4.18 SEM micrographs for the experiments conducted in Table 4.14.

N
""

63

Figure 4.19 Effect of solvent on the particle size.

From the results shown in Table 4.14 and Figure 4.19, particles produced by
Acetone were bigger than the particles produced by DCM. Mixture of Acetone and DCM
also gave bigger particles compared to DCM. From the SEM micrographs shown in
Figure 4.16, shape of the particle varies with the solvent. Diamond shaped particles were
produced by using pure acetone and mixture of Acetone and DCM. Rectangular shaped
particles were formed by using DCM.

4.8.3 Effect of Pressure on the Particle Size
The effect of initial pressure (50 - 70 bars) was explored for this process while keeping
all the remaining parameters constant. Increase in pressure, increases the depressurization
time and hence increases the agglomeration of particles during precipitation and hence
increase the particle size.
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Table 4.15 Effect of Pressure on the Particle Size

Exp

Pressure
(bar)

Conc.
(gm/ml)

Solvent

Size
(μm)

SD

1

70

0.015

DCM

8.64

6.35

2

65

0.015

DCM

7.45

4.05

3

60

0.015

DCM

5

4.61

4

55

0.015

DCM

4.44

4.26

5

50

0.015

DCM

2.43

1.85

Results shown in Table 4.15 and Figure 4.20 indicate that an increase in initial
pressure resulted in the increase in the particle size of Griseofulvin drug particles. The
particle size distribution was also found to be widened with an increase in pressure. For
this process smaller particles were produced by maintaining lower pressures.

Figure 4.20 Effect of pressure on the particle size.

Figu.·e 4.21

SEM micrographs for the experiments conducted in Table 4.15.
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Table 4.16 Concentration of Components in Aqueous Suspension

CHAPTER 5
CONCLUSIONS AND RECOMMONDATIONS

This study focused on two processes for the production of fine particles namely Liquid
Anti solvent using concentric ultrasonic nozzle and the other using subcritical CO 2 .
Various process parameters on particle size and size distribution were studied.
Griseofulvin with size ranging from 10 - 2 microns was precipitated with a narrow
particle size distribution, It was observed that the morphology of particles was always
diamond shaped or tetragonal. Efforts were made to control the particle size using a
combination of ultrasound and additives such as polymer and surfactants for Liquid
antisolvent using ultrasonic nozzle. Use of ultrasound increases micromixing and
surfactant and polymers decrease surface tension of solution. Enhanced micromixing and
reduction in surface tension increases nucleation rate and reduces particle size. Further
adsorption of polymers/surfactants and their complexes on the particle surface control the
particle growth. Addition of electrolyte further enhances the interaction between
polymers and surfactants and further narrows down the particle size distribution. For the
process of particle precipitation using CO 2 it is observed that lower pressure, lower the
initial solute concentration and non polar solvent decrease the particle size and
distribution. Generation of higher supersaturation with controlled growth can precipitate
ultrafine particles in this process,
It can be recommended that there should be a detailed study conducted on the
mechanism of particle formation so as to be able to tune the particle size and size
distribution by varying process parameters.
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